Published in Clin Cancer Res on May 27, 2016
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J (2017) 0.75
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget (2016) 0.75
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics (2017) 0.75
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis (2017) 0.75
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 38.62
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 5.73
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 3.51
p300/CBP and cancer. Oncogene (2004) 3.13
Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (2011) 2.86
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med (2015) 2.41
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood (2002) 2.38
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet (2014) 2.17
The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One (2013) 2.00
DNMT3A mutations in myeloproliferative neoplasms. Leukemia (2011) 1.95
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2013) 1.93
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67
RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet (2014) 1.57
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One (2009) 1.53
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol (2015) 1.49
Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res (2014) 1.47
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia (2014) 1.43
IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leuk Lymphoma (2010) 1.42
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia (2014) 1.38
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood (2013) 1.33
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene (2001) 1.25
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia (2013) 1.17
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun (2015) 1.14
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget (2014) 1.12
IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia (2011) 1.08
H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation. Proc Natl Acad Sci U S A (2013) 1.08
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene (2012) 1.07
A modified method for whole exome resequencing from minimal amounts of starting DNA. PLoS One (2012) 1.00
SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability. Cancer Res (2014) 0.99
CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now. Biochem Soc Trans (2013) 0.98
Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet (2015) 0.93
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes Cancer (2014) 0.87
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia (2014) 0.85
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol (2005) 0.82
Chromatin remodeler mutations in human cancers: epigenetic implications. Epigenomics (2014) 0.79
Current and potential epigenetic targets in multiple myeloma. Epigenomics (2014) 0.78
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol (2017) 0.84
Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res (2016) 0.80
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biol Blood Marrow Transplant (2016) 0.75
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol (2017) 0.75
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood (2017) 0.75
Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants. Clin Cancer Res (2016) 0.75